Danish Media Stock News

H. Lundbeck A/S recently presented six-month real-world data from its 12-month INFUSE study at the 2026 Headache Cooperative of the Pacific Conference in Ojai, California, highlighting outcomes for adults with migraine treated with Vyepti (eptinezumab) after prior preventive anti-CGRP failures. The data showed meaningful improvements in multiple patient-reported outcomes, including an average 6.3 additional "good days" per month, reinforcing the clinical relevance of switching to intravenous...

Genmab (CPSE:GMAB) is back in focus after reporting that worldwide net trade sales of DARZALEX, as disclosed by Johnson & Johnson, reached US$14.351b in 2025. This figure feeds directly into Genmab’s royalty income. See our latest analysis for Genmab. Genmab’s DARZALEX update lands after a strong run in the shares, with a 10.67% 90 day share price return and a 49.98% 1 year total shareholder return. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent...

Jyske Bank has completed its share buyback programme announced in February 2025, repurchasing 5,398,229 shares, or 8.97% of its share capital, for DKK 2,249.99 million by 30 January 2026. Following the programme, Jyske Bank holds 3,309,528 treasury shares, equal to 5.38% of its share capital, underlining management’s clear capital allocation priorities. With this substantial buyback now finished, we’ll explore how such active capital management shapes Jyske Bank’s investment narrative and...

Ambu (CPSE:AMBU B) is back in focus after CEO Britt Meelby Jensen joined a Danish delegation to China and presented a Chinese made endoscope, highlighting a potential shift in the company’s geographic risk profile. See our latest analysis for Ambu. The new China focus comes after a tough run for shareholders, with the share price at DKK84.7 and a 1-year total shareholder return decline of 36%, extending a 5-year total shareholder return drop of 74%. This suggests momentum has been fading...

Danske Bank has completed its DKK 5,000,000,000 share buy-back programme, repurchasing 19,179,623 shares that are expected to be cancelled subject to shareholder approval at the March 26, 2026 annual general meeting. This move underscores a capital position that allows meaningful cash returns to investors and signals management’s confidence in the bank’s current trajectory. We’ll now examine how the completed DKK 5,000,000,000 buy-back and planned share cancellation shape Danske Bank’s...

ALK-Abelló (CPSE:ALK B) is back in focus after regulators in Europe issued a positive opinion on extending EURneffy marketing authorisation to include a 1 mg nasal adrenaline spray for younger children. See our latest analysis for ALK-Abelló. The CHMP opinion appears to have been a fresh catalyst, with ALK-Abelló’s 1-day share price return of 2.12% standing out against a 30-day share price return decline of 6.44%. Its 1-year total shareholder return of 34.35% and 3-year total shareholder...

Novo Nordisk and Aspect Biosystems have moved into a new phase of their diabetes cell-therapy partnership, with Aspect acquiring key stem cell and hypoimmune engineering rights, plus integrated Novo Nordisk R&D and manufacturing capabilities, while Novo Nordisk keeps options to expand its role and earn milestones and royalties on future products. By handing operational leadership of next-generation cell therapies to Aspect while retaining financial and later-stage participation rights, Novo...

Event driven spotlight on Carlsberg stock Carlsberg (CPSE:CARL B) has agreed to sell its 50% stake in Tibet based Lhasa Brewery to Tibet Development, exiting a joint venture that faced management disputes and weaker unit level financial performance. The deal, completing just before Carlsberg’s annual results, removes a contested asset from the portfolio and gives investors fresh context for assessing the group’s earnings profile and capital allocation priorities. See our latest analysis for...

NKT announced that it has signed final contracts under its framework agreement with SSEN Transmission to deliver 525 kV HVDC on- and offshore power cable systems for the Western Isles and Spittal to Peterhead links in Scotland, adding about €2.00 billion to its high-voltage order backlog. Beyond expanding NKT’s backlog, the projects highlight the company’s role in enabling large-scale grid reinforcement for Great Britain’s electricity transmission network. Next, we’ll examine how securing...

As the eurozone economy continues its modest recovery, with consumer and business confidence on the rise despite mixed performances in major stock indexes, investors are keenly observing growth companies that demonstrate strong insider ownership. In this context, stocks with high insider ownership can be particularly appealing as they often reflect a management team’s confidence in their company’s long-term potential and alignment with shareholder interests.

Recently, Ambu’s CEO Britt Meelby Jensen joined a Danish life science delegation to China, presenting a new Chinese-made endoscope as part of efforts to deepen cooperation and diversify the company’s global value chain away from a more difficult US market. This move highlights how Ambu is reconfiguring its manufacturing and market exposure to tap Chinese healthcare demand while reducing reliance on a single geography. We’ll now examine how Ambu’s increased focus on Chinese manufacturing and...

Key Insights The considerable ownership by individual investors in TORM indicates that they collectively have a greater...

Novo Nordisk (CPSE:NOVO B) is back in focus after the US launch of its oral Wegovy pill, where early prescription data suggest a strong start that many investors view as a potential turning point. See our latest analysis for Novo Nordisk. The early strength of the Wegovy pill launch comes after a tough stretch, with Novo Nordisk reporting a 1-year total shareholder return decline of 37.4%, even as the 90-day share price return sits at 17% and the 5-year total shareholder return remains up...

INFUSE study data puts Vyepti in focus for Lundbeck investors H. Lundbeck (CPSE:HLUN B) has drawn investor attention after presenting six month real world INFUSE study data on its migraine treatment Vyepti at the 2026 Headache Cooperative of the Pacific conference. See our latest analysis for H. Lundbeck. The INFUSE update lands after a mixed stretch for the shares, with a 1-day share price return of 1.06% to DKK42.12 contrasting with weaker 7-day, 90-day and 1-year total shareholder return...

DSV recently broke ground on a new US$14.5 million, 88,258‑square‑meter regional headquarters and logistics facility in Mesa, Arizona, which will consolidate air, sea, road, and contract logistics services and ultimately employ about 160–200 people. By positioning this hub near Phoenix‑Mesa Gateway Airport to support sectors such as semiconductors and advanced manufacturing, DSV is tying its growth plans to Arizona’s expanding high‑tech supply chain ecosystem. We will now examine how this...

Vattenfall has ordered Vestas turbines featuring low-emissions steel for the 63 MW Clashindarroch II wind farm in Scotland, marking the first time this lower-impact material has been used in a commercial wind project. This step highlights how Vestas is integrating cleaner materials into turbine manufacturing, potentially reshaping sustainability standards across the wind supply chain. We’ll now explore how this pioneering use of low-emissions steel could influence Vestas’ investment...

It's not a stretch to say that Carlsberg A/S' ( CPH:CARL B ) price-to-earnings (or "P/E") ratio of 16.8x right now...

Amid renewed trade and geopolitical uncertainty, the pan-European STOXX Europe 600 Index recently ended 0.98% lower, reflecting a broader decline across major European stock indexes. Despite this downturn, opportunities may exist for investors seeking stocks that could be trading below their estimated value, particularly in sectors where business activity remains positive and confidence is on the rise. Identifying undervalued stocks often involves looking at companies with strong fundamentals...

In January 2026, Genmab reported that worldwide 2025 net trade sales of DARZALEX, as reported by Johnson & Johnson, reached US$14.35 billion, generating ongoing royalty revenue for Genmab, and released positive topline Phase 3 EPCORE DLBCL-1 results showing epcoritamab monotherapy improved progression-free survival in relapsed or refractory DLBCL versus standard regimens. The combination of a very large, royalty-generating DARZALEX franchise and clinically meaningful Phase 3 data for...

Vestas Wind Systems (CPSE:VWS) is back in focus after European countries agreed on plans for 100 GW of shared offshore wind capacity in the North Sea, and Vestas shares rose 5.2% on the news. See our latest analysis for Vestas Wind Systems. The North Sea pact has arrived on top of a strong run in Vestas’ shares, with a 90 day share price return of 46.61% and a 1 year total shareholder return of 103.98% from a starting point that had seen weaker multi year outcomes. Recent gains, including a...

A.P. Møller - Mærsk has resumed part of its Red Sea–Suez Canal sailings with conditional routing, while also appointing Charles van der Steene as Regional Managing Director for the Indian Subcontinent, Middle East & Africa from 1 January 2026 and progressing a share buy-back program of up to DKK 14.40 billion announced in February 2025. Together, these developments highlight Maersk’s mix of operational risk management, regional leadership continuity and capital return decisions at a time of...

Amid renewed trade and geopolitical uncertainty, the European stock market has seen declines, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite these challenges, business activity in the eurozone remains positive, offering a glimmer of optimism for investors seeking opportunities in undervalued stocks. In this context, identifying stocks trading below their intrinsic value can be crucial for investors looking to capitalize on potential market inefficiencies and position...

Share buy-back launch puts Aktieselskabet Schouw (CPSE:SCHO) in focus Aktieselskabet Schouw (CPSE:SCHO) has moved into the spotlight after launching a share buy-back programme of up to DKK 240 million through 2026, a capital allocation decision that can influence both valuation and trading interest. See our latest analysis for Aktieselskabet Schouw. That buy-back announcement lands after a steady run in the share price, with a 30-day share price return of 4.67% and a 90-day share price return...

The Board of Directors of Alm. Brand (CPSE:ALMB) has recommended an ordinary dividend of DKK 0.66 per share for the 2025 financial year, corresponding to a total payout of DKK 0.9b. See our latest analysis for Alm. Brand. At a share price of DKK18.16, Alm. Brand has had a mildly weaker recent patch, with a 1 month share price return of a 3.51% decline, even though its 1 year total shareholder return of 25.93% points to momentum that has built over a longer horizon. If this dividend news has...